Brexit: Industry should keep Timelines for Batch Testing Facilities
Recommendation
15/16 October 2024
Understanding the Importance of GMP
In a reminder sent out to stakeholders the European Medicines Agency (EMA) points out that - independent from the extension of the date for the UK's withdrawal from the EU ('Brexit') to 31 October 2019 - Marketing Authorisation Holders (MAHs) should use the remaining time to complete all necessary preparations. This means that by 1 January 2020 all batch testing sites must be fully transferred to the remaining EU27 Member States and/or EEA countries. Also the necessary regulatory submissions must be completed by then. This includes MAHs who have the permission to perform quality control testing in the UK even after Brexit. "The transfer should be completed quickly and in principle by the end of 2019 at the latest", EMA writes on their website with Brexit related guidance documents. Companies should check this page regularly.
Related GMP News
18.09.2024Lack of GMP Training and related Documentation: What Deviations can be found in FDA Warning Letters?
04.09.2024Switzerland: Changes for the Qualification of QPs (Responsible Person; RP in Switzerland)
04.09.2024Insufficient Root Cause Analysis leads to FDA Warning Letter
28.08.2024Switzerland to implement Measures to combat Shortages of Medicines
26.06.202410 points on how the FDA's CDER monitors the Quality of Medicinal Products
08.05.2024EMA Plans for the next three Years